Cimzia (certolizumab pegol), Vetter Pharma-Fertigung, Germany Cimzia (certolizumab pegol) is used for approved inflammatory conditions including rheumatoid arthritis. Medicine delivery from Europe with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.

Rheumatoid arthritis

Treatment of moderate and highly active rheumatoid arthritis in adults (from 18 years of age):

• in combination with methotrexate with insufficient response to treatment with basic anti-inflammatory drugs (DMARDs), including methotrexate;
• as monotherapy when further treatment with methotrexate is intolerant or inappropriate.

Cimzia^®when used in combination with methotrexate has been shown to reduce the progression of joint damage assessed by radiography and improve physical functions.

Crohn's disease

Treatment of Crohn's disease with moderate and high degrees of disease activity in adults when DMARD therapy is ineffective.

Axial spondyloarthritis

Cimzia^®indicated for the treatment of severe active axial spondyloarthritis in adults, including:

• severe active ankylosing spondylitis with insufficient response to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or their intolerance in adults;
• severe active axial spondylitis without radiological signs of AS, but with objective signs of inflammation, manifested in an increase in the concentration of CRP and/or with corresponding changes in magnetic resonance imaging (MRI), with an insufficient response to NSAID therapy or with their intolerance.

Psoriatic arthritis

Treatment of active psoriatic arthritis in adults:

• in combination with methotrexate in case of insufficient response to DMARD therapy;
• as monotherapy in case of intolerance or inappropriateness of further treatment with methotrexate.